Drug Trial Radar · NCT00817063
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
Last checked: Nov 20, 2026Latest source record: Apr 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
599
Actual
Start
Jan 8, 2009
Primary completion
Apr 26, 2012
Study completion Apr 26, 2012
Sponsor
- Lead sponsor
- Stiefel, a GSK CompanyIndustry
- Sponsor type
- Industry
- Collaborators
- Basilea Pharmaceutica
- First posted
- Jan 6, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the safety and efficacy of alitretinoin in the treatment of severe chronic hand eczema that does not respond to treatment with potent topical steroids.
Conditions
- Eczema
Interventions
alitretinoinDrug
Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks
PlaceboDrug
Patients receive matching placebo for up to 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Responded as Per Physician's Global Assessment (PGA) at Week 24Time frame: Week 24 (end-of-treatment)
Locations
70 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama, Birmingham
Birmingham, Alabama
Radiant Research Inc.
Tucson, Arizona
Johnson Dermatology
Fort Smith, Arkansas
Dermatology Research of Arkansas
Little Rock, Arkansas
Hull Dermatology
Rogers, Arkansas
Shahram Jacobs, MD, Inc.
Encino, California
University of California, San Diego Dermatology Clinical Trials Unit
La Jolla, California
Dermatology Research Associates
Los Angeles, California
Laser and Dermatology Center
Marina del Rey, California
Integrated Research Group
Riverside, California
University of California, Davis
Sacramento, California
Therapeutics Clinical Research
San Diego, California
East Bay Psoriasis Treatment Center
San Ramon, California
Stanford University Dept of Dermatology
Stanford, California
Solano Clinical Research, Dow Pharmaceutical Sciences
Vallejo, California
Longmont Clinic, P.C.
Longmont, Colorado
Western State Clinical Research Inc.
Wheat Ridge, Colorado
George Washington University - Medical Faculty Associates
Washington D.C., District of Columbia
Park Avenue Dermatology, PA
Orange Park, Florida
Palm Beach Research Center
West Palm Beach, Florida
Toccoa Clinic Medical Associates
Toccoa, Georgia
Saltzer Medical Group
Nampa, Idaho
Michael Bukhalo MD
Arlington Heights, Illinois
Dermassociates, Ltd
Belleville, Illinois
Schaumburg Dermatology
Schaumburg, Illinois
Dundee Dermatology
West Dundee, Illinois
Deaconess Clinic, Inc.
Evansville, Indiana
Indiana University Dermatology
Indianapolis, Indiana
The Dermatology Center
New Albany, Indiana
Dermatology Center of Indiana/Indiana Clinical Trials Center
Plainfield, Indiana
Kansas City Dermatology, PA
Overland Park, Kansas
American Dermatology Association
Shawnee Mission, Kansas
Kansas Medical Clinic
Topeka, Kansas
Dermatology Specialists
Louisville, Kentucky
Derm Research, PLLC
Louisville, Kentucky
Tulane University Health Sciences, Dermatology Dept
New Orleans, Louisiana
Hamzavi Dermatology Clinic
Fort Gratiot, Michigan
Silverton Skin Institute
Grand Blanc, Michigan
Grekin Skin Institute
Warren, Michigan
MAPS Applied Research Center
Edina, Minnesota
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.